# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price...
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises th...
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from...
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate ...
HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $66 price ta...
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label...
- Form 13G